These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1078 related items for PubMed ID: 29241450

  • 21. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [Abstract] [Full Text] [Related]

  • 22. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T, Udaka K, Shibata H, Sekimoto E, Ozaki S.
    Rinsho Ketsueki; 2017 Jul; 58(12):2369-2374. PubMed ID: 29332868
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Decitabine. Acute myeloid leukaemia: no progress.
    Prescrire Int; 2014 Apr; 23(148):92-4. PubMed ID: 24860891
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group.
    Lancet Oncol; 2009 Mar; 10(3):223-32. PubMed ID: 19230772
    [Abstract] [Full Text] [Related]

  • 30. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G, Chromik K, Woźniczka K, Kopińska AJ, Boral K, Dworaczek M, Koclęga A, Armatys A, Panz-Klapuch M, Markiewicz M.
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F, European ALMA + Investigators.
    Leuk Lymphoma; 2018 May; 59(5):1113-1120. PubMed ID: 28838276
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
    Gemuenden C, Benz R, Senn O, Goede JS, Manz MG, Gerber B.
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
    [Abstract] [Full Text] [Related]

  • 34. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [Abstract] [Full Text] [Related]

  • 35. Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
    Seymour JF, Döhner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H.
    Leuk Lymphoma; 2017 Jun; 58(6):1412-1423. PubMed ID: 27739920
    [Abstract] [Full Text] [Related]

  • 36. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM.
    Cancer; 2017 Aug 15; 123(16):3050-3060. PubMed ID: 28387922
    [Abstract] [Full Text] [Related]

  • 37. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W, Zhou Z, Chen L, Wang X.
    Clin Lymphoma Myeloma Leuk; 2021 Jun 15; 21(6):e530-e544. PubMed ID: 33716056
    [Abstract] [Full Text] [Related]

  • 38. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
    Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B.
    Genes (Basel); 2020 Jul 24; 11(8):. PubMed ID: 32722092
    [Abstract] [Full Text] [Related]

  • 39. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.
    Br J Haematol; 2016 Jan 24; 172(2):238-45. PubMed ID: 26568032
    [Abstract] [Full Text] [Related]

  • 40. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H.
    Lancet Oncol; 2021 Nov 24; 22(11):1597-1608. PubMed ID: 34672961
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.